EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to Cynatine ® and maintenance of normal joint mobility pursuant to Article 13(5) of Regulation (EC) No 1924/2006

EFSA Publication; Inge Tetens

doi:10.2903/j.efsa.2012.3004

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to Cynatine ® and maintenance of normal joint mobility pursuant to Article 13(5) of Regulation (EC) No 1924/2006

EFSA Publication, Inge Tetens

2 Citations (Scopus)

Abstract

Following an application from Roxlor Nutra LLC, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Cynatine® and maintenance of normal joint mobility. The Panel considers that Cynatine®, which is a keratin powder extracted from sheep wool, is sufficiently characterised. The claimed effect proposed by the applicant refers to “joint flexibility”. The Panel considers that maintenance of normal joint mobility is a beneficial physiological effect. The applicant presented one unpublished human intervention study as being pertinent to the health claim. The Panel notes that the study was specifically designed to identify patients with clinical diagnosis of osteoarthritis, and considers that normal cells and tissues are genetically (gene expression) and functionally different from osteoarthritic cells and tissues, and therefore may respond differently to interventions with exogenous substances. In addition, the mechanisms involved in the onset and/or progression of osteoarthritis are largely unknown. It would have to be established, therefore, that an intervention which has an effect on the progression of the disease (in patients with osteoarthritis) would also have an effect on its onset (subjects without the disease). The Panel considers that no conclusions can be drawn from this study for the scientific substantiation of the claim. The Panel concludes that a cause and effect relationship has not been established between the consumption of Cynatine® and maintenance of normal joint mobility.
© European Food Safety Authority, 2012

Original language	English

Publisher	European Food Safety Authority
DOIs	https://doi.org/10.2903/j.efsa.2012.3004
Publication status	Published - 2012
Externally published	Yes

Access to Document

10.2903/j.efsa.2012.3004

Cite this

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to Cynatine ® and maintenance of normal joint mobility pursuant to Article 13(5) of Regulation (EC) No 1924/2006. / Publication, EFSA; Tetens, Inge.

European Food Safety Authority, 2012.

Research output: Book/Report › Report › Research › peer-review

@book{fdd3d0d5d9fc431685f76926f7bcd9e1,

title = "EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to Cynatine {\textregistered} and maintenance of normal joint mobility pursuant to Article 13(5) of Regulation (EC) No 1924/2006",

abstract = "Following an application from Roxlor Nutra LLC, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Cynatine{\textregistered} and maintenance of normal joint mobility. The Panel considers that Cynatine{\textregistered}, which is a keratin powder extracted from sheep wool, is sufficiently characterised. The claimed effect proposed by the applicant refers to “joint flexibility”. The Panel considers that maintenance of normal joint mobility is a beneficial physiological effect. The applicant presented one unpublished human intervention study as being pertinent to the health claim. The Panel notes that the study was specifically designed to identify patients with clinical diagnosis of osteoarthritis, and considers that normal cells and tissues are genetically (gene expression) and functionally different from osteoarthritic cells and tissues, and therefore may respond differently to interventions with exogenous substances. In addition, the mechanisms involved in the onset and/or progression of osteoarthritis are largely unknown. It would have to be established, therefore, that an intervention which has an effect on the progression of the disease (in patients with osteoarthritis) would also have an effect on its onset (subjects without the disease). The Panel considers that no conclusions can be drawn from this study for the scientific substantiation of the claim. The Panel concludes that a cause and effect relationship has not been established between the consumption of Cynatine{\textregistered} and maintenance of normal joint mobility.{\textcopyright} European Food Safety Authority, 2012",

keywords = "Cynatine{\textregistered}, Joints, Mobility, Osteoarthritis, Chronic inflammation, Health claims",

author = "EFSA Publication and Inge Tetens",

year = "2012",

doi = "10.2903/j.efsa.2012.3004",

language = "English",

publisher = "European Food Safety Authority",

}

TY - RPRT

T1 - EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to Cynatine ® and maintenance of normal joint mobility pursuant to Article 13(5) of Regulation (EC) No 1924/2006

AU - Publication, EFSA

AU - Tetens, Inge

PY - 2012

Y1 - 2012

N2 - Following an application from Roxlor Nutra LLC, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Cynatine® and maintenance of normal joint mobility. The Panel considers that Cynatine®, which is a keratin powder extracted from sheep wool, is sufficiently characterised. The claimed effect proposed by the applicant refers to “joint flexibility”. The Panel considers that maintenance of normal joint mobility is a beneficial physiological effect. The applicant presented one unpublished human intervention study as being pertinent to the health claim. The Panel notes that the study was specifically designed to identify patients with clinical diagnosis of osteoarthritis, and considers that normal cells and tissues are genetically (gene expression) and functionally different from osteoarthritic cells and tissues, and therefore may respond differently to interventions with exogenous substances. In addition, the mechanisms involved in the onset and/or progression of osteoarthritis are largely unknown. It would have to be established, therefore, that an intervention which has an effect on the progression of the disease (in patients with osteoarthritis) would also have an effect on its onset (subjects without the disease). The Panel considers that no conclusions can be drawn from this study for the scientific substantiation of the claim. The Panel concludes that a cause and effect relationship has not been established between the consumption of Cynatine® and maintenance of normal joint mobility.© European Food Safety Authority, 2012

AB - Following an application from Roxlor Nutra LLC, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Cynatine® and maintenance of normal joint mobility. The Panel considers that Cynatine®, which is a keratin powder extracted from sheep wool, is sufficiently characterised. The claimed effect proposed by the applicant refers to “joint flexibility”. The Panel considers that maintenance of normal joint mobility is a beneficial physiological effect. The applicant presented one unpublished human intervention study as being pertinent to the health claim. The Panel notes that the study was specifically designed to identify patients with clinical diagnosis of osteoarthritis, and considers that normal cells and tissues are genetically (gene expression) and functionally different from osteoarthritic cells and tissues, and therefore may respond differently to interventions with exogenous substances. In addition, the mechanisms involved in the onset and/or progression of osteoarthritis are largely unknown. It would have to be established, therefore, that an intervention which has an effect on the progression of the disease (in patients with osteoarthritis) would also have an effect on its onset (subjects without the disease). The Panel considers that no conclusions can be drawn from this study for the scientific substantiation of the claim. The Panel concludes that a cause and effect relationship has not been established between the consumption of Cynatine® and maintenance of normal joint mobility.© European Food Safety Authority, 2012

KW - Cynatine®

KW - Joints

KW - Mobility

KW - Osteoarthritis

KW - Chronic inflammation

KW - Health claims

U2 - 10.2903/j.efsa.2012.3004

DO - 10.2903/j.efsa.2012.3004

M3 - Report

BT - EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to Cynatine ® and maintenance of normal joint mobility pursuant to Article 13(5) of Regulation (EC) No 1924/2006

PB - European Food Safety Authority

ER -